Menovazan

INSTRUCTION FOR MEDICAL USE OF THE MEDICINAL PRODUCT MENOVAZAN (MENOVASAN)

Composition:

Active substances: 1 g of ointment contains 25 mg of racemic menthol, 10 mg of novocaine (procaine hydrochloride), 10 mg of anesthesin (benzocaine);

Excipients: mineral oil, white soft paraffin, emulsifier T-2, purified water.

Pharmaceutical form. Ointment.

Main physicochemical properties: white ointment with the smell of menthol.

Pharmacotherapeutic group. Antipruritic agents. ATC code D04A X.

Pharmacological properties.

Pharmacodynamics.

Menovazan is a combined preparation, and its properties are determined by the action of active components. In particular, due to the selective effect of menthol on cold receptors, the ointment causes a sensation of cold, while its irritant effect may vary slightly with anesthesia. Reflexively, menthol alters vascular tone. This applies both to superficial vessels and to those located deeper. Novocaine has sufficiently pronounced anesthetic activity. It does not alter vascular tone. Anaesthesin produces surface anesthesia. The combination of these components in a single preparation ensures the ability to reversibly impair excitability and conductivity of nerve receptors and pathways upon direct contact with them, exert irritant and distracting effects, suppress excitation of nerve fiber membranes, reduce the amplitude of action potential, increase the depolarization threshold of nerve fiber membranes, slow the rate of rise of the action potential, and reduce the degree of excitation in nerve elements.

Pharmacokinetics.

Not studied.

Clinical characteristics.

Indications.

Neuralgias, myalgias, arthralgias; dermatoses accompanied by itching.

Contraindications.

Hypersensitivity to the components of the drug.

Special safety precautions.

Do not apply to skin exhibiting signs of allergic reaction, to facial skin, or to damaged skin.

Interaction with other medicinal products and other forms of interaction.

It is not recommended to use simultaneously with other topical agents (may enhance effects of locally acting anesthetic drugs). Components of the drug (novocaine, anestezin) weaken the antibacterial action of sulfonamide drugs.

When using any other medicinal products concurrently, inform your doctor.

Special precautions.

Use during pregnancy or breastfeeding. There is no experience with the use of the drug during pregnancy or breastfeeding.

Ability to affect reaction rate when driving or operating machinery.

Driving or operating machinery should be avoided, as dizziness may occur.

Method of Administration and Dosage.

Apply externally 2–3 times a day by rubbing into painful or affected areas of the skin. The duration of treatment depends on the form and course of the disease, as well as on the nature of concomitant therapy. The maximum daily dose is 9 g.

Children.

Do not use in children under 12 years of age.

Overdose.

With prolonged use, dizziness, general weakness, decreased arterial pressure, and allergic reactions are possible.

If these symptoms occur, discontinue the drug, wash off any residue from the skin surface with water, and consult a physician. Treatment is symptomatic.

Side effects.

Allergic reactions are possible (including hyperemia, skin irritation, itching, rash, swelling, urticaria), contact dermatitis.

Shelf life.

3 years. Do not use the drug after the expiry date stated on the packaging.

Storage conditions.

Store at a temperature not exceeding 25 ºC in a place inaccessible to children.

Packaging.

40 g in a tube in a carton.

Release category. Over-the-counter.

Manufacturer.

LLC "DKP "Pharmaceutical Factory".

Manufacturer's address and location of business activity.

4, Korolova St., Stanyshivka, Zhytomyr district, Zhytomyr region, 12430, Ukraine.